<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066583</url>
  </required_header>
  <id_info>
    <org_study_id>501-1-07-18-15</org_study_id>
    <nct_id>NCT03066583</nct_id>
  </id_info>
  <brief_title>Effectiveness of Trephination With Platelet Rich Plasma or Placebo in a Primary Meniscal Tear Treatment</brief_title>
  <acronym>Prolotherapy</acronym>
  <official_title>Prospective, Randomised, Double Blinded Trial Comparing Effectiveness of Platelet Rich Plasma or Placebo in a Primary Meniscal Tear Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre of Postgraduate Medical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre of Postgraduate Medical Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare meniscal healing augmented or without augmentation with platelet rich
      plasma in primary meniscal tear treatment (prolotherapy). The assessments will include
      validated, disease specific, patient oriented outcome measures. Results of this study will
      help ascertain whether platelet rich plasma may improve meniscal healing rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of meniscal in the knee integrity is pivotal and lack or partial role of the
      meniscus increases rate of joint degeneration. Partial meniscal removal is the most popular
      procedure and meniscal repair remain in minority of arthroscopic surgeries. As criteria of
      inclusion to meniscal repair are very rough, still success rates of meniscal repair remain in
      the 60-80% range for isolated repairs. This rate is greater when performed with ACL
      reconstruction. The investigators believe that augmentation with platelet rich plasma as
      prolotherapy ill induce healing without the need for arthroscopy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of meniscal healing by MR scanning</measure>
    <time_frame>by 1 year</time_frame>
    <description>The primary outcome measures will be assessment of meniscal healing integrity by MR scanning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>12 weeks, 6months, 1year post procedure</time_frame>
    <description>Pain Visual Analog Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score scale</measure>
    <time_frame>12 weeks, 6months, 1year post procedure</time_frame>
    <description>Knee injury and Osteoarthritis Outcome Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee - Subjective Knee Evaluation Form</measure>
    <time_frame>12 weeks, 6months, 1year post procedure</time_frame>
    <description>International Knee Documentation Committee - Subjective Knee Evaluation Form</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Meniscus Lesion</condition>
  <arm_group>
    <arm_group_label>trephination with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>meniscal repair with trephination and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trephination with platelet rich plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>meniscal repair with trephination and platelet rich plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trephination with placebo</intervention_name>
    <description>trephination under US guidance and placebo injection</description>
    <arm_group_label>trephination with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trephination with platelet rich plasma</intervention_name>
    <description>trephination under US guidance and platelet rich plasma injection</description>
    <arm_group_label>trephination with platelet rich plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Complete horizontal 10 mm in length

          -  Tear located in the vascular portion of the meniscus, only in red-white zone

          -  Single tear of the medial and/or lateral meniscus

          -  Meniscal injury 1 -18 month prior surgery

          -  Skeletally mature patients 18-55 years of age

        Exclusion Criteria:

          -  discoid meniscus

          -  arthritic changes (Kellgren Lawrence scale &gt;2)

          -  non repairable meniscus

          -  degenerative or presence of crystals in meniscus

          -  concomitant procedure (acl reconstruction, microfracturing, trephination)

          -  inflammatory diseases (i.e. rheumatoid arthritis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafal Kaminski</last_name>
    <role>Principal Investigator</role>
    <affiliation>PCME, Otwock, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rafal Kaminski, MD PhD</last_name>
    <phone>+48227794031</phone>
    <phone_ext>431</phone_ext>
    <email>rkaminski@spskgruca.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Orthopaedics and Traumatology, Postgraduate Center for Medical Education, Professor A. Gruca Teaching Hospital</name>
      <address>
        <city>Otwock</city>
        <state>Mazowieckie</state>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafal Kaminski, MD PhD</last_name>
      <phone>+48227794031</phone>
      <phone_ext>431</phone_ext>
      <email>rkaminski@spskgruca.pl</email>
    </contact>
    <contact_backup>
      <last_name>Stanislaw Pomianowski, MD PhD Prof</last_name>
      <phone>+48227794031</phone>
      <phone_ext>481</phone_ext>
      <email>spom@spskgruca.pl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre of Postgraduate Medical Education</investigator_affiliation>
    <investigator_full_name>Rafał Kamiński</investigator_full_name>
    <investigator_title>Deputy Chair of Division</investigator_title>
  </responsible_party>
  <keyword>meniscus repair</keyword>
  <keyword>platelet rich plasma</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

